NCT02121925

Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up

LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 227 (actual)
• Sponsor: Myriad Genetic Laboratories, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment decisions of Surgeons when added to standard clinical-pathological parameters in patients with early stage NSCLC.The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006).This registry is specific to Surgeons (ONC003). Outcomes measures on lung cancer relapse and death from any cause will be collected.

Conditions

• Lung Cancer
• NSCLC
• Lung Adenocarcinoma

Timeline

• Start date: 2014-05-01
• Primary completion: 2017-06-30
• Completion: 2017-07-31
• First posted: 2014-04-24
• Last updated: 2017-09-05

Locations

1 site across 1 country: United States